Single-center, Open-label, Non-placebo-controlled, Single-dose Study in Healthy Male Participants to Determine the Pharmacokinetics of BAY 1817080 Oral Solution (Part A) and to Investigate the Pharmacokinetics, Metabolic Disposition and Mass Balance of [14C]BAY 1817080 Oral Solution (Part B)
Latest Information Update: 30 Jan 2023
At a glance
- Drugs Eliapixant (Primary)
- Indications Cough; Endometriosis; Overactive bladder
- Focus Pharmacokinetics
- Sponsors Bayer
- 16 Feb 2021 Status changed from active, no longer recruiting to completed.
- 10 Feb 2021 Planned End Date changed from 5 Feb 2021 to 11 Feb 2021.
- 05 Feb 2021 Planned End Date changed from 21 Jan 2021 to 5 Feb 2021.